OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial introductions	39
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	39
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	35
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	30
Future options for long-acting HIV treatment and prevention	26
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	23
The sounds of silencing: dynamic epigenetic control of HIV latency	23
Editorial introductions	22
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	21
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	20
Harnessing natural killer cells to target HIV-1 persistence	20
Editorial introduction	19
Challenges towards an AIDS-free generation in Africa and Asia	17
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	17
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	17
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	16
The double burden: navigating HIV co-infections with HCV, HBV, and Mtb	16
Loneliness and social isolation in people with HIV	15
Editorial introduction	15
Editorial introduction	14
New latency-promoting agents for a block-and-lock functional cure strategy	14
Persistent elite controllers as the key model to identify permanent HIV remission	14
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	14
Estrogen depletion and immune activation and inflammation in women with HIV	13
Balancing polypharmacy and comorbidity management: cardiovascular health	13

Editorial introduction	13
Public health surveillance and outbreak preparedness for mpox	13
Impact of coronavirus disease 2019 on co-morbidities in HIV	13
Defining multimorbidity in people with HIV – what matters most?	13
The origins of new SARS-COV-2 variants in immunocompromised individuals	13
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	13
Stigma as a facilitator of the 2022 mpox outbreak	13
Integrating substance use services into HIV care: an underused implementation science opportunity	12
Viral and immune predictors of HIV posttreatment control	12
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	12
Aging of adult lifetime survivors with perinatal HIV	12
The multifaceted nature of HIV tissue reservoirs	11
Learned young: HIV-1 germline-targeting vaccination in infants	11
New vector and vaccine platforms: mRNA, DNA, viral vectors	11
Mpox and the impact on people with HIV	10
Role of follicular homing natural killer cells in HIV infection	10
Broadly neutralizing antibodies for HIV treatment and cure approaches	9
Gender and sex considerations in HIV and bone health	9
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	9
Obesity among women with HIV	9
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	8
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	8
Editorial introductions	8
Roadmap for spatial transcriptomics of HIV in tissues	8
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	8
Host factors predisposing to kidney disease in people with HIV	8
The severity of COVID-19 across the spectrum of HIV	8
Causes and outcomes of hepatic fibrosis in persons living with HIV	8
Metabolic dysfunction-associated steatotic liver disease in people with HIV	8
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	8
Editorial introductions	8
Editorial introduction	8
Strategies to target the central nervous system HIV reservoir	7
Mpox in 2026: what we knew, what we have learned, and what we still have to learn	7
Innate immune mechanisms in HIV elite controllers	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Innovative models of care supporting people aging with HIV	7
Contemporary issues in gynecologic and reproductive health for women with HIV	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	7
Persistent HIV-1 transcription during ART: time to reassess its significance?	7
Editorial introductions	7
Editorial introductions	7